Research News
View articles by month and year
-
Tamoxifen Plus Chemo Boosts Survival
Hormonal therapy and chemotherapy boosts survival for women with early breast cancer.
-
Aromatase Inhibitors Offer Better Survival Than Tamoxifen for Postmenopausal Women
Switching to an aromatase inhibitor after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.
-
Too Many Women Stop Taking Tamoxifen Early
Many women stop taking adjuvant hormonal therapy medicine earlier than prescribed by their doctors.
-
Switching from Tamoxifen to Aromatase Inhibitor Improves Survival
Switching to Arimidex after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.
-
Femara Reduces Recurrence Risk
Hormonal therapy has been shown to be very effective in reducing the risk of hormone-receptor-positive, early-stage breast cancer coming back (recurring) in postmenopausal women. To reduce the risk of ...
